tbuckley/cabot-search huggingface dataset:
Diagnostic Accuracy and Acceptability of the Primary Care Posttraumatic Stress Disorder Screen for the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (Fifth Edition) Among US Veterans
Authors: Michelle J. Bovin, Rachel Kimerling, Frank W. Weathers, Annabel Prins, Brian P. Marx, Edward P. Post, Paula P. Schnurr
Journal: JAMA Network Open (2021)

Posttraumatic stress disorder (PTSD) is a serious mental health disorder that can be effectively treated with empirically based practices. PTSD screening is essential for identifying undetected cases and providing patients with appropriate care.To determine whether the Primary Care PTSD screen for the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (PC-PTSD-5) is a diagnostically accurate and acceptable measure for use in Veterans Affairs (VA) primary care clinics.This cross-sectional, diagnostic accuracy study enrolled participants from May 19, 2017, to September 26, 2018. Participants were recruited from primary care clinics across 2 VA Medical Centers. Session 1 was conducted in person, and session 2 was completed within 30 days via telephone. A consecutive sample of 1594 veterans, aged 18 years or older, who were scheduled for a primary care visit was recruited. Data analysis was performed from March 2019 to August 2020.In session 1, participants completed a battery of questionnaires. In session 2, a research assistant administered the PC-PTSD-5 to participants, and then a clinician assessor blind to PC-PTSD-5 results conducted a structured diagnostic interview for PTSD.The range of PC-PTSD-5 cut points overall and across gender was assessed, and diagnostic performance was evaluated by calculating weighted κ values.In total, 495 of 1594 veterans (31%) participated, and 396 completed all measures and were included in the analyses. Participants were demographically similar to the VA primary care population (mean [SD] age, 61.4 [15.5] years; age range, 21-93 years) and were predominantly male (333 participants [84.1%]) and White (296 of 394 participants [75.1%]). The PC-PTSD-5 had high levels of diagnostic accuracy for the overall sample (area under the receiver operating characteristic curve [AUC], 0.927; 95% CI, 0.896-0.959), men (AUC, 0.932; 95% CI, 0.894-0.969), and women (AUC, 0.899, 95% CI, 0.824-0.974). A cut point of 4 ideally balanced false negatives and false positives for the overall sample and for men. However, for women, this cut point resulted in high numbers of false negatives (6 veterans [33.3%]). A cut point of 3 fit better for women, despite increasing the number of false positives. Participants rated the PC-PTSD-5 as highly acceptable.The PC-PTSD-5 is an accurate and acceptable screening tool for use in VA primary care settings. Because performance parameters will change according to sample, clinicians should consider sample characteristics and screening purposes when selecting a cut point.
Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change
Authors: Anita D’Souza, Ruta Brazauskas, Angela Dispenzieri, Julie Panepinto, Kathryn E. Flynn
Journal: Blood Cancer Journal (2021)

Abstract We conducted a prospective cohort study in newly diagnosed systemic light chain (AL) amyloidosis patients ( N = 59) to study patient-reported outcomes (PROs) through the first year. The median age was 68 years with 42% female, 8% Black, and 78% lambda subtype. Organ involvement was cardiac in 66%, renal in 58%, with 25% having 3 or greater organs involved. Between baseline and 3 months, all PROMIS ® -29 domain scores worsened by 0.4–4.1 points except anxiety which improved by 2.1 points. By 1 year, scores improved compared to the greatest decline at 3 months, most statistically significant for global physical health, physical function, and fatigue. On stage-adjusted survival analysis, in addition to baseline global physical and mental health, domains measuring physical function, fatigue, anxiety, depression, and social roles were associated with 1-year survival. At 1 year, PROMIS measures were associated with NT-proBNP changes and hematologic response. Among patients with an NT-proBNP response, the improvement was seen in physical function, social roles, global mental health, and anxiety. Among patients with an NT-proBNP progression, worsening was seen with anxiety, depression, sleep, and global mental health. Measuring and tracking PROs in patients with AL amyloidosis is important and these important outcomes can be used as correlative endpoints in clinical care/research.
Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer—Reply
Authors: Srikala S. Sridhar, Keyue Ding, Wendy R. Parulekar
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 14778: Reduction of Cardiometabolic Risk in African Americans Utilizing the 2019 American College of Cardiology/American Heart Association Primary Prevention Nutrition Guidelines
Authors: Kim A Williams, Ibtihaj A M Fughhi, Sharon Gates, Stephen Sawyer, Setri Fugar, Hena Patel, Darrius Chambers, Ronald McDaniel, Jochen R Reiser, Terry Mason
Journal: Circulation (2019)

Introduction: Cardiovascular disease (CVD) mortality in the USA is increasing, consistent with the rise in obesity and type II diabetes mellitus. The African American (AA) population carries the hi...
First-Line Choice for Severe Aplastic Anemia in Children: Transplantation from a Haplo-Identical Donor Versus Immunosuppressive Therapy
Authors: Zhengli Xu, Yifei Cheng, Yuan-Yuan Zhang, Jun Wu, Feng-Rong Wang, Xiao-Dong Mo, Yu-Hong Chen, Wei Han, Jinsong Jia, Yu Wang, Xiao-Hui Zhang, Xiao-Jun Huang, Leping Zhang, Lan-Ping Xu
Journal: Blood (2017)
Applications of Mobile Health Technology in Surgical Innovation
Authors: Oliver Aalami, Angela Ingraham, Shipra Arya
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Examination of Racial and Ethnic Differences in Deceased Organ Donation Ratio Over Time in the US
Authors: Amber B. Kernodle, Wanying Zhang, Jennifer D. Motter, Brianna Doby, Luckmini Liyanage, Jacqueline Garonzik-Wang, Kyle R. Jackson, Brian J. Boyarsky, Allan B. Massie, Tanjala S. Purnell, Dorry L. Segev
Journal: JAMA Surgery (2021)

Historically, deceased organ donation was lower among Black compared with White populations, motivating efforts to reduce racial disparities. The overarching effect of these efforts in Black and other racial/ethnic groups remains unclear.To examine changes in deceased organ donation over time.This population-based cohort study used data from January 1, 1999, through December 31, 2017, from the Scientific Registry of Transplant Recipients to quantify the number of actual deceased organ donors, and from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research Detailed Mortality File to quantify the number of potential donors (individuals who died under conditions consistent with organ donation). Data were analyzed from December 2, 2019, to May 14, 2020.Race and ethnicity of deceased and potential donors.For each racial/ethnic group and year, a donation ratio was calculated as the number of actual deceased donors divided by the number of potential donors. Direct age and sex standardization was used to allow for group comparisons, and Poisson regression was used to quantify changes in donation ratio over time.A total of 141 534 deceased donors and 5 268 200 potential donors were included in the analysis. Among Black individuals, the donation ratio increased 2.58-fold from 1999 to 2017 (yearly change in adjusted incidence rate ratio [aIRR], 1.05; 95% CI, 1.05-1.05; P < .001). This increase was significantly greater than the 1.60-fold increase seen in White individuals. Nevertheless, substantial racial differences remained, with Black individuals still donating at only 69% the rate of White individuals in 2017 (P < .001). Among other racial minority populations, changes were less drastic. Deceased organ donation increased 1.80-fold among American Indian/Alaska Native and 1.40-fold among Asian or Pacific Islander populations, with substantial racial differences remaining in 2017 (American Indian/Alaska Native population donation at 28% and Asian/Pacific Islander population donation at 85% the rate of the White population). Deceased organ donation differences between Hispanic/Latino and non-Hispanic/Latino populations increased over time (4% lower in 2017).The findings of this cohort study suggest that differences in deceased organ donation between White and some racial minority populations have attenuated over time. The greatest gains were observed among Black individuals, who have been the primary targets of study and intervention. Despite improvements, substantial differences remain, suggesting that novel approaches are needed to understand and address relatively lower rates of deceased organ donation among all racial minorities.
Urban living in healthy Tanzanians is associated with an inflammatory status driven by dietary and metabolic changes
Authors: Godfrey S. Temba, Vesla Kullaya, Tal Pecht, Blandina T. Mmbaga, Anna C. Aschenbrenner, Thomas Ulas, Gibson Kibiki, Furaha Lyamuya, Collins K. Boahen, Vinod Kumar, Leo A. B. Joosten, Joachim L. Schultze, Andre J. van der Ven, Mihai G. Netea, Quirijn de Mast
Journal: Nature Immunology (2021)
Abstract PO013: SNP rs1982 in the 3’UTR of placenta-specific protein 1 (PLAC1) is associated with endometrial cancer survival
Authors: Eric J. Devor, Jesus Gonzalez-Bosquet, Kimberly K. Leslie
Journal: Clinical Cancer Research (2021)

Abstract Placenta-specific protein 1 (PLAC1) is a small (212aa) secreted protein normally only expressed on the apical surfaces of syncytiotrophoblasts. However, over the past two decades we and other investigators have shown that human cancers and, in particular, cancers of the human reproductive tract, induce PLAC1 expression. In gynecologic cancers, PLAC1 expression has been shown to be associated with risk, histology and TP53 mutation status. A previously unassessed informative SNP rs1982 (A&amp;gt;C) lies in the 3’ untranslated region of the PLAC1 gene. We have begun to explore the utility of this SNP by genotyping a panel of 75 endometrial cancers. The panel is composed of 29 endometrial adenocarcinomas, 10 papillary serous adenocarcinomas, 9 mixed Mullerian tumors, 6 mixed histologies, 2 tumors identified as displaying complex atypia and 1 neuroendocrine tumor. High molecular weight genomic DNA was extracted from these tumors and SNP genotypes determined by directly sequencing a 312bp PCR amplicon generated by the primers: rs1982for: GAGGATTGGTCTCTTCACACAG; rs1982rev: ACAATGTCTGGCCCATACTAAA SNP genotypes were then evaluated against a variety of clinical variables including age, BMI, tobacco use, Charlson Index, co-morbidities, stage, grade, myometrial invasion, recurrence, and death by cancer using both univariate and multivariate logistic regression. Progression-free and overall survival were assessed by Cox Proportional Hazard ratio. Results show that CC homozygotes have increased progression-free and overall survival though neither reached statistical significance. However, several clinical variables were statistically associated with different rs1982 genotypes. Charlson co-morbidity Index was positively associated with presence of the wild-type A allele (OR = 1.61; 1.06 - 2.69; p&amp;lt;0.05), while death from disease was negatively associated (OR = 0.15; 0.03 – 0.64; p&amp;lt;0.02). These differences hold when accounting for other co-variates in the multivariate analysis. These data support further exploration of this SNP in gynecologic cancers. Citation Format: Eric J. Devor, Jesus Gonzalez-Bosquet, Kimberly K. Leslie. SNP rs1982 in the 3’UTR of placenta-specific protein 1 (PLAC1) is associated with endometrial cancer survival [abstract]. In: Proceedings of the AACR Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment; 2020 Nov 9-10. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(3_Suppl):Abstract nr PO013.
Abstract 14484: Enhanced Levels of Soluble CD40 Ligand Exacerbate Platelet Aggregation and Thrombus Formation via CD40-Dependent TRAF-2/Rac1/p38 MAPK Signaling Pathway
Authors: Ahmed Hachem, Daniel Yacoub, Jean-Fran cois Théorêt, Marc-Antoine Gillis, Walid Mourad, Yahye Merhi
Journal: Circulation (2010)

Objective: We aimed to determine the impact and the signaling mechanisms of sCD40L on platelet function. Methods and Results: sCD40L strongly enhances activation and aggregation of washed human pla...
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt
Authors: Christophe Bureau, Dominique Thabut, Caroline Jezequel, Isabelle Archambeaud, Louis D’alteroche, Sêbastien Dharancy, Patrick Borentain, Frederic Oberti, Aurélie Plessier, Victor de Ledinghen, Nathalie Ganne-Carrié, Nicolas Carbonell, Vanessa Rousseau, Agnès Sommet, Jean Marie Péron, Jean Pierre Vinel
Journal: Annals of Internal Medicine (2021)

The efficacy of rifaximin in the secondary prevention of overt hepatic encephalopathy (HE) is well documented, but its effectiveness in preventing a first episode in patients after transjugular intrahepatic portosystemic shunt (TIPS) has not been established.To determine whether rifaximin prevents overt HE after TIPS compared with placebo.Randomized, double-blind, multicenter, placebo-controlled trial. (ClinicalTrials.gov: NCT02016196).197 patients with cirrhosis undergoing TIPS for intractable ascites or prevention of variceal rebleeding.Patients were randomly assigned to receive rifaximin (600 mg twice daily) or placebo, beginning 14 days before TIPS and continuing for 168 days after the procedure.The primary efficacy end point was incidence of overt HE within 168 days after the TIPS procedure.An episode of overt HE occurred in 34% (95% CI, 25% to 44%) of patients in the rifaximin group (n = 93) and 53% (CI, 43% to 63%) in the placebo group (n = 93) during the postprocedure period (odds ratio, 0.48 [CI, 0.27 to 0.87]). Neither the incidence of adverse events nor transplant-free survival was significantly different between the 2 groups.The study's conclusion applies mainly to patients with alcoholic cirrhosis, who made up the study population. The potential benefit of rifaximin 6 months after TIPS and beyond remains to be investigated.In patients with cirrhosis treated with TIPS, rifaximin was well tolerated and reduced the risk for overt HE. Rifaximin should therefore be considered for prophylaxis of post-TIPS HE.French Public Health Ministry.
Noncoding RNA processing by DIS3 regulates chromosomal architecture and somatic hypermutation in B cells
Authors: Brice Laffleur, Junghyun Lim, Wanwei Zhang, Yiyun Chen, Evangelos Pefanis, Jonathan Bizarro, Carolina R. Batista, Lijing Wu, Aris N. Economides, Jiguang Wang, Uttiya Basu
Journal: Nature Genetics (2021)
YjbH mediates the oxidative stress response and infection by regulating SpxA1 and the phosphoenolpyruvate-carbohydrate phosphotransferase system (PTS) in <i>Listeria monocytogenes</i>
Authors: Changyong Cheng, Xiao Han, Jiali Xu, Jing Sun, Kang Li, Yue Han, Mianmian Chen, Houhui Song
Journal: Gut Microbes (2021)

(2021). YjbH mediates the oxidative stress response and infection by regulating SpxA1 and the phosphoenolpyruvate-carbohydrate phosphotransferase system (PTS) in Listeria monocytogenes. Gut Microbes: Vol. 13, No. 1, 1884517.
Preventing cardiovascular events after pneumonia with aspirin: one step forward, but still many to go
Authors: Martin Kolditz, Tobias Welte
Journal: European Respiratory Journal (2021)

Cardiovascular (CV) diseases and lower respiratory tract infections dominate human burden of disease across the world. Combined, they cause nearly 20 million or 36% of annual global deaths [1]. Additionally, both are linked together and interact bidirectionally: underlying CV disease is an established risk factor for the development of pneumonia and poor prognosis during pneumonia [2, 3], and vice versa , the role of pneumonia as risk factor for CV complications and new-onset CV disease has been demonstrated [4–6]. Preventing cardiovascular events after pneumonia by aspirin: another step forward, but questions remain <https://bit.ly/2H5z4OB>
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Authors: Grzegorz S. Nowakowski, Fangxin Hong, David W. Scott, William R. Macon, Rebecca L. King, Thomas M. Habermann, Nina Wagner-Johnston, Carla Casulo, James L. Wade, Gauri G. Nagargoje, C. M. Reynolds, Jonathon B. Cohen, Nadia Khan, Jennifer E. Amengual, Kristy L. Richards, R. F. Little, John P. Leonard, Jonathan W. Friedberg, Lale Kostakoglu, Brad S. Kahl, Thomas E. Witzig
Journal: Journal of Clinical Oncology (2021)

Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell-like (ABC) subtype. Eastern Cooperative Oncology Group (ECOG)-ACRIN trial E1412 was a randomized phase II study comparing R2CHOP versus R-CHOP in untreated DLBCL.
Abstract 12373: Stage a Heart Failure Trends in the Social Media Era
Authors: Ashley Ezema, Quentin R Youmans, Allen S Anderson, Kamari C Jackson, Edwin Mandieka, Ramael Ohiomoba, Oluseyi Princewill, Clyde W Yancy, Ike S Okwuosa
Journal: Circulation (2019)

Background: Stage A Heart Failure (HF) represents those at risk for developing HF. These risk factors include hypertension, diabetes, coronary artery disease, and obesity. In this study we examine ...
Maintaining Safety with SARS-CoV-2 Vaccines
Authors: Giovanni Rolla, Luisa Brussino, Iuliana Badiu
Journal: New England Journal of Medicine (2021)

To the Editor: In the review article by Castells and Phillips on vaccines for the prevention of infection with SARS-CoV-2 (published on Dec. 30 at NEJM.org), 1 the authors describe cases of anaphylaxis associated with the Pfizer-BioNTech messenger RNA (mRNA) vaccine.The estimated incidence of anaphylaxis is 1 in 100,000 injections, as compared with an expected incidence of 1 in 1 million injections. 2 The incidence of anaphylaxis after vaccination with the quadrivalent human papillomavirus (HPV) vaccine (Gardasil) has been estimated at 1 in 190,000 injections 3 ; this incidence is similar to that reported for the Pfizer-BioNTech vaccine.Polysorbate 80 is an excipient in Gardasil, and we identified polysorbate 80 as the culprit in a case of anaphylaxis that occurred in a young girl after the third intramuscular administration of that vaccine. 4 Castells and Phillips note that the implications for the future use of SARS-CoV-2 vaccines, which are commonly formulated with polysorbate 80 (with a structure similar to that of polyethylene glycol [PEG]), are unknown.Allergists should be aware that cross-reactive immediate hypersensitivity to macrogols (PEGs) and polysorbates can occur.We have reported 5 a case of multiple drug reaction due to hypersensitivity to PEGs of a wide variety of molecular weights, from PEG 80 to macrogol 6000.
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Authors: Kenneth B Gordon, Peter Foley, James G Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi, Andrew Blauvelt
Journal: The Lancet (2021)
Integrating youth mental health into cash transfer programmes in response to the COVID-19 crisis in low-income and middle-income countries
Authors: Annette Bauer, Emily Garman, David McDaid, Mauricio Avendano, Philipp Hessel, Yadira Díaz, Ricardo Araya, Crick Lund, Paulo Malvasi, Alicia Matijasevich, A-La Park, Cristiane Silvestre Paula, Carolina Ziebold, Annie Zimmerman, Sara Evans-Lacko
Journal: The Lancet Psychiatry (2021)

Social protection measures can play an important part in securing livelihoods and in mitigating short-term and long-term economic, social, and mental health impacts of the COVID-19 pandemic. In particular, cash transfer programmes are currently being adapted or expanded in various low-income and middle-income countries to support individuals and families during the pandemic. We argue that the current crisis offers an opportunity for these programmes to focus on susceptible young people (aged 15-24 years), including those with mental health conditions. Young people living in poverty and with mental health problems are at particular risk of experiencing adverse health, wellbeing, and employment outcomes with long-term consequences. They are also at risk of developing mental health conditions during this pandemic. To support this population, cash transfer programmes should not only address urgent needs around food security and survival but expand their focus to address longer-term mental health impacts of pandemics and economic crises. Such an approach could help support young people's future life chances and break the vicious cycle between mental illness and poverty that spirals many young people into both socioeconomic and mental health disadvantage.
History of Eczema Among Black and White Peanut Allergic Children
Authors: Jialing Jiang, Jamie Fierstein, Lucy Bilaver, Alexandria Bozen, Isabel Galic, Pamela Newmark, Christopher Warren, Audrey Brewer, Jacqueline Pongracic, Annika Chura, Amal Assa'ad, Aame Andy-Nweye, Susan Fox, Mahboobeh Mahdavinia, Mary Tobin, Adam Robinson, Amaziah Coleman, Hemant Sharma, Andrea Pappalardo, Ruchi Gupta
Journal: Journal of Allergy and Clinical Immunology (2021)